JAC Advance Access originally published online on October 12, 2006
Journal of Antimicrobial Chemotherapy 2006 58(6):1246-1249; doi:10.1093/jac/dkl411
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Genetic characterization of the dihydrofolate reductase gene of Pneumocystis jirovecii isolates from Portugal
1 Unidade de Protozoários Oportunistas/VIH e outras Protozooses, Unidade de Parasitologia e Microbiologia Médicas (UPMM) Instituto de Higiene e Medicina Tropical, Rua da Junqueira 96, 1349-008 Lisboa, Portugal 2 Clínica das Doenças Infecciosas Hospital de Santa Maria, Avenida Prof. Egas Moniz, 1649-028 Lisboa, Portugal
Received 24 April 2006; returned 24 July 2006; revised 14 September 2006; accepted 14 September 2006
*Corresponding author. Tel: +351-21-3652638; Fax: +351-21-3632105; E-mail: omatos{at}ihmt.unl.pt
Objectives: The aim of the present study was to evaluate the genetic variation of Pneumocystis jirovecii dihydrofolate reductase (DHFR) gene in an immunocompromised Portuguese population and to investigate the possible association between DHFR genotypes and P. jirovecii pneumonia (PcP) prophylaxis with co-trimoxazole.
Methods: One hundred and thirty-eight P. jirovecii isolates were submitted to DHFR genetic characterization by PCR and sequencing.
Results: In the studied population, 72.7% of the patients presented sequences identical to the wild-type sequence of the P. jirovecii DHFR gene and 27.3% presented point substitutions. A total of nine substitution sites were identified; four synonymous substitutions at nucleotide positions 201, 272, 312 and 381 were detected in 31 patients. Five non-synonymous substitutions were observed, leading to the DHFR mutations Leu-13
Ser, Asn-23
Ser, Ser-31
Phe, Met-52
Leu and Ala-67
Val. With the exception of the polymorphism at position 312 and the mutation at codon 52, all polymorphisms were reported in this study for the first time.
Conclusions: Our results suggest that DHFR gene polymorphisms are frequent in the Portuguese immunocompromised population but do not seem to be associated with PcP prophylaxis failure (P = 0.748 and P = 0.730).
Keywords: polymorphisms , mutations , co-trimoxazole , drug resistance